KRAS and oculocutaneous albinism: Targeting the RAF–MEK–ERK pathway with MEK inhibitors, enhances growth inhibition and apoptosis in OCa harboring KRAS or BRAF mutations suggesting their dependence on RAS–RAF–MEK–ERK signaling for survival [5].